Bearish Bet on Pharma Stock Doubled Investors' Money
Subscribers to Schaeffer's Leverage Trader service more than doubled their investment with our Bristol-Myers Squibb Co (NYSE:BMY) September 63 put recommendation, all in in just two weeks.
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
It's been a rough year to invest in pharma stocks. The industry is adjusting to a sector that is less reliant on Covid-19 vaccines and is adapting to the effects of inflation as well as pressure fr...
Bristol Myers plans to double experimental treatments to expand research pipeline
Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with incr...
Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II
Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it sh...
Judge withdraws from Medicare drug price case after stock ownership is revealed
Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference.
Medicare drug price negotiations may have a muted impact on drugmakers in the near term
Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.
Multiple Reasons to Keep Off This Pharma Stock
Bristol-Myers Squibb Co (NYSE:BMY) is down 0.7% to trade at $62.42 at last check, after the Biden administration included the pharmaceutical name's blood thinner Eliquis in its list of 10 prescrip...
The technical trade: T, BMY & DLR
Katie Stockton, Fairlead Strategies founder, joins 'Power Lunch' to discuss the technical support for AT&T, Bristol-Myers Squibb and Digital Realty Trust.
Here are the three most used drugs on the Medicare price negotiation list
The Biden administration unveiled the much-awaited list officially kicking off a process that aims to control rising drug costs in the U.S.
10 Drugs Selected for Medicare Price Reduction
We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.
Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion
Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.
Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition
Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. ...
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper. Traditionally, most biotech stock drug candidates fail.
Related Companies